Resperate is a non-drug option to further lower patients' high blood pressure with no side effects and no drug interactions. Results of 6 clinical studies have been published in peer-reviewed journals, including the American Journal of Hypertension. Resperate delivers an average 14/9 mmHg sustained

blood pressure reduction within 8 weeks of proper use (15 minutes a day, 3-4 times per week). The Scientific Advisory Board for Resperate includes many of the world's leading hypertension experts, including past presidents of the American, European and International Societies of Hypertension. The

underlying physiological mechanism of action of Low Frequency Respiratory Pacing technology, as deployed in Resperate, was recently discussed in the AHA Hypertension Primer, Third Edition textbook. A reprint of the relevant chapter is available by fax request.